Catalyst OriginalJul 26, 2026
The FDA peptide vote is not an approval
The important thing about the FDA advisory vote is what it is and what it is not. The Pharmacy Compounding Advisory Committee recommended adding six peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, to the 503A Bulks List. If FDA finalizes that path, state-licensed compounding pharmacies could have a legal ingredient route for prescription preparations. It is not FDA approval, not a finding that the products are safe or effective, and not permission to treat internet vials as medicine. The practical reason the vote matters is that patient demand already exists outside ordinary drug approval. Some advisers treated compounding as harm reduction: if demand is already real, a supervised pharmacy path may create more oversight than unsupervised access. That argument is about quality control and access reality, not proof that the clinical claims have been earned.
